Akèy › Kansè tete negatif triple › Oregon › Eugene
Etid klinik pou Kansè tete negatif triple nan Eugene, OR
3 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Eugene (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Willamette Valley Cancer Institute and Research Center, Eugene
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Willamette Valley Cancer Institute, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Atlanta, GA20 etid
- Arlington, VA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Eugene
- Kansè Poumon ki pa ti selil13 etid
- Kansè ovè9 etid
- Kansè Endomèt8 etid
- Kansè nan tete7 etid
- Lukemi lenfositè kwonik6 etid
- Myelom Miltip6 etid
- Kansè Metastatik6 etid
- Kansè (tout kalite)6 etid
- Itilizasyon Dwòg ak Depandans5 etid
- Kansè poumon5 etid
- Degeneresans makile5 etid
- Obèsite4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.